Peer-reviewed veterinary case report
Continuous dialysis treatment and outcome prediction in dogs
By Raskansky, Hilli et al.·Published in Journal of veterinary internal medicine·2025·Ben-Shemen Specialist Referral Center·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Continuous Renal Replacement Therapy: Application of Kidney Disease Improving Global Outcomes Guidelines for Treatment Prescription in Dogs With Acute Kidney Injury and Outcome Prediction.
- Species:
- dog
Plain-English summary
A group of 30 dogs with acute kidney injury (AKI) received continuous renal replacement therapy (CRRT) to help manage their condition. Before starting treatment, the veterinarians used specific scoring systems to predict which dogs might recover. After treatment, 37% of the dogs survived and showed significant improvement in their kidney function, with lower levels of waste products in their blood. The study found that the scoring systems were effective in predicting outcomes, and the CRRT protocol used was safe and beneficial for the dogs.
People also search for: dog kidney injury treatment · continuous renal replacement therapy for dogs · dog kidney disease prognosis
Abstract
BACKGROUND: Continuous renal replacement therapy (CRRT) is routinely used in human patients with acute kidney injury (AKI) but studies in dogs are scarce. OBJECTIVE: To describe CRRT in dogs and assess the utility of a previously validated scoring system for dogs with AKI undergoing hemodialysis, and the Acute Patient Physiological and Laboratory Evaluation (APPLE/APPLE) scores, for outcome prediction. ANIMALS: Thirty, client-owned dogs. METHODS: Cases were retrospectively reviewed. Prognostic scores were calculated upon admission and before CRRT initiation. The CRRT effluent dose followed the KDIGO guidelines. Receiver operating characteristic curves (ROCC) were constructed to evaluate the prognostic utility of these scores. RESULTS: Median (IQR) serum creatinine (mg/dL) at CRRT initiation, at discharge, and 3 months after discharge were 9.4 (7.4), 3.4 (1), and 1.3 (0.3) respectively. Median (IQR) treatment duration and total number of treatments were 24 (18.5) h and 2 (2) treatments, respectively. The prescribed median (IQR) CRRT effluent dose was 29 (18.5) mL/kg/h. Median (IQR) overall time-average concentration for urea and creatinine were 92 (60) mg/dL and 3.7 (1.7) mg/dL, respectively. The normalized weekly median (IQR) standardized Kt/V was 2.41 (2.29). Eleven dogs (37%) survived to discharge/3-months after treatment. Areas under the ROCC for the APPLE/APPLEscores before CRRT initiation were 0.99 (95% CI, 0.99-1.00) and 0.91 (95% CI, 0.81-1.00), respectively. Optimal cutoff points were < 35 for the APPLEand < 23 for the APPLE, yielding sensitivities/specificities of 100% (95% CI, 74.12%-100.0%)/94.7% (95% CI, 75.36%-99.73%) and 90.9% (95% CI, 62.26%-99.53%)/78.95% (95% CI, 56.67%-91.49%), respectively. CONCLUSION: The APPLE scores, unlike clinicopathological findings or the Segev score, proved to be a highly discriminatory prognostic tool. Additionally, the human-derived, KDIGO guideline-based CRRT protocol proved safe and efficacious in dogs undergoing CRRT.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40613773/